Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441282 · ClinicalTrials.gov registry record
Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression
A clinical trial, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- 26
- Enrollment target
NCT03441282 is a clinical trial that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 26 participants.
The verdict
NCT03441282 was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The concept of precision medicine - taking individual variability into account when planning preventions and interventions - is not new but is quickly gaining attention in this age of powerful methodology of patient characterization and development of tools to analyze large sets of data. Oncology is the most obvious field in which this information has been readily applied. Increasing focus, nationally and internationally, on developing broad databases of patient genetic information and research efforts evaluating those data will, hopefully, lead to the development and application of evidence-based data enhancing the practice of all fields of medicine. It has yet to become obvious how this information can best be applied to the field of anesthesiology. Most genomics work in anesthesia has been focused in the area of pain medicine. There is a known genetic influence on the potency of opioid-induced analgesia, however; a genetic component of opioid-induced respiratory depression has yet to be thoroughly evaluated. Respiratory depression plays a role in clinical care - from procedures requiring sedation with monitored anesthesia care to treating post-opertative pain and chronic pain - but perhaps its largest current role in the public arena is the unfortunate deaths caused by side effects due to drug overdose. Personalized medicine remains on the horizon for the field of anesthesia, but, as genetic testing becomes more affordable and mainstream in clinical practice, the potential applications are broad. Most readily would be its incorporation into development of patient specific pain regimens. Respiratory depression is a potentially lethal side effect of opioid therapy. In light of the opioid epidemic and CDC-scrutiny of opioid use, determining genetic profiles susceptible to respiratory depression could prove useful in further tailoring the treatment of pain both in the perioperative setting and in the chronic pain management setting.
Interventions
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2025-05-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03441282
The ClinicalTrials.gov registry entry for NCT03441282 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fentanyl is the first listed.
NCT03441282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03441282 about?
NCT03441282 is a clinical study titled "Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression". The concept of precision medicine - taking individual variability into account when planning preventions and interventions - is not new but is quickly gaining attention in this age of powerful methodology of patient characterization and development of tools to analyze large sets of data. Oncology is...
What is the current status of trial NCT03441282?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2018-10-30. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT03441282?
The interventions under investigation include: Fentanyl (DRUG).
Who is sponsoring clinical trial NCT03441282?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.